Left-sided heart failure is treated with a combination of medications, lifestyle adjustments, and in some cases implanted devices or surgery. The exact approach depends on whether your heart’s pumping strength is reduced or preserved, how severe your symptoms are, and how your body responds to initial treatment. Most people with left-sided heart failure can be managed effectively with the right medication regimen and self-care strategies, though treatment is ongoing and requires regular monitoring.
Reduced vs. Preserved: Why the Type Matters
Left-sided heart failure falls into two main categories, and they’re treated differently. In heart failure with reduced ejection fraction (HFrEF), the left ventricle can’t pump forcefully enough. In heart failure with preserved ejection fraction (HFpEF), the heart pumps with normal strength but the ventricle is stiff and doesn’t fill properly. Your ejection fraction, measured by echocardiogram, tells your care team which type you have. Normal is 50% or higher. Below 40% is considered reduced.
This distinction shapes your entire treatment plan. HFrEF has the most robust evidence behind its drug therapies, with four core medication classes shown to reduce death and hospitalization. HFpEF treatment is more limited but has gained new options in recent years.
The Four Pillars of Medication for Reduced Ejection Fraction
Current guidelines from the American Heart Association and American College of Cardiology recommend starting all four core drug classes as soon as possible in HFrEF. These are sometimes called “quadruple therapy” or the “four pillars,” and together they improve survival, reduce hospital readmissions, and help people feel better day to day.
- A drug that blocks harmful hormone signals. Your body responds to a weakened heart by ramping up hormones that retain fluid and constrict blood vessels. ACE inhibitors and ARBs block this cycle. A newer combination drug (sacubitril/valsartan, sold as Entresto) goes a step further by also boosting a natural hormone that helps the heart relax and shed excess fluid. It’s now preferred over older options when tolerated. The typical starting dose is taken twice daily and doubled every two to four weeks to reach the target maintenance dose.
- A beta blocker. This slows your heart rate and lowers blood pressure, giving your heart less work to do with each beat. Over months, beta blockers can actually help the heart muscle recover some pumping strength.
- A mineralocorticoid receptor antagonist (MRA). This blocks a hormone called aldosterone that causes the body to hold onto salt and water. It also reduces scarring in heart muscle tissue.
- An SGLT2 inhibitor. Originally developed for diabetes, this class of drug helps the kidneys release excess sodium and fluid. It reduces heart failure hospitalizations and death regardless of whether you have diabetes.
One important safety note: if you’re switching from an ACE inhibitor to sacubitril/valsartan, you need a 36-hour gap between the last dose of one and the first dose of the other. Taking them too close together can cause a dangerous drop in blood pressure.
Treatment for Preserved Ejection Fraction
HFpEF has fewer proven drug therapies, but the landscape has shifted. SGLT2 inhibitors now carry the strongest recommendation for HFpEF, with clinical trials showing clear benefits for symptoms and hospitalizations. MRAs and ARBs may also be considered, though the evidence is less definitive. Beyond medications, treatment focuses heavily on managing the conditions that drive HFpEF: high blood pressure, atrial fibrillation, obesity, and diabetes. Controlling these underlying problems is a cornerstone of feeling better.
Managing Fluid Buildup
Congestion, the fluid overload that causes swelling, breathlessness, and weight gain, is the most common reason people with heart failure end up in the hospital. Diuretics (often called “water pills”) are the frontline tool. Loop diuretics are used most frequently and work by forcing the kidneys to excrete more sodium and water.
Sometimes the body stops responding well to a single diuretic, a problem called diuretic resistance. When this happens, a second type of diuretic (typically a thiazide) can be added to work on a different part of the kidney and restore fluid loss. In clinical trials, this combination approach has been tested alongside other agents to break through resistance. If your diuretic seems to stop working and you notice rapid weight gain or worsening swelling, that’s a sign your regimen may need adjustment.
Fluid restriction is not required for everyone with heart failure, but it may help in specific situations. For people with severe heart failure or low blood sodium levels, limiting fluids to 1 to 1.5 liters per day can relieve congestion. For others, a cap of 1.5 to 2 liters daily may be reasonable. Your care team will tell you whether fluid restriction applies to you based on your blood work and symptoms.
Sodium, Diet, and Daily Habits
Reducing sodium intake is a standard recommendation. Most heart failure guidelines suggest staying well below the typical Western diet’s sodium load, which averages over 3,400 mg per day. Practical steps include cooking at home more often, reading nutrition labels, choosing fresh over processed foods, and avoiding canned soups, deli meats, and restaurant meals that tend to be sodium-heavy.
Daily weight monitoring is one of the simplest and most effective self-management tools. Weigh yourself each morning, after using the bathroom and before eating, on the same scale. A gain of two or more pounds overnight, or three to five pounds in a week, often signals fluid retention before you notice swelling or shortness of breath. Catching it early gives you and your care team time to adjust diuretics before symptoms escalate.
Exercise and Cardiac Rehabilitation
Exercise is safe and beneficial for most people with stable heart failure. Cardiac rehabilitation programs provide supervised, structured exercise alongside education and support. Guidelines recommend starting with two to three sessions per week at a light to moderate intensity, with each session lasting 15 to 30 minutes. Over time, the goal is to build up to 45 to 60 minutes per session, three to seven days per week for moderate-intensity activity.
If you don’t have access to formal rehab or a baseline exercise test, intensity can be guided by how hard the activity feels. On a standard effort scale of 6 to 20 (where 6 is sitting still and 20 is maximum exertion), you should aim for roughly 11 to 14, the range where you’re breathing harder but can still hold a conversation. For people with irregular heart rhythms or limited heart rate response, perceived effort is more reliable than tracking heart rate.
Regular exercise improves exercise tolerance, quality of life, and in some studies has reduced hospitalizations. Walking, cycling, and water-based exercise are all good options. The key is consistency and gradual progression rather than intensity.
Implanted Devices
When medications alone aren’t enough, implanted devices can help. Two types are commonly used in left-sided heart failure.
An implantable cardioverter-defibrillator (ICD) monitors your heart rhythm continuously and delivers a shock if it detects a life-threatening arrhythmia. Most patients with an ejection fraction below 35% despite optimal medication therapy are candidates.
Cardiac resynchronization therapy (CRT) uses a specialized pacemaker to coordinate the timing of your heart’s contractions. It’s designed for people whose electrical signals travel abnormally slowly through the heart, causing the left and right sides to beat out of sync. You’re typically a candidate if your ejection fraction is below 35%, you’ve been on optimal medications for at least three months, and your QRS duration (a measure of electrical signal speed on an EKG) is greater than 130 milliseconds with a specific pattern called left bundle branch block. The wider the QRS, the more likely CRT is to help. Many devices combine CRT with a defibrillator in a single unit.
CRT is not beneficial, and may cause harm, in people with a QRS duration below 130 milliseconds or an ejection fraction above 50%.
Iron Deficiency: A Common Overlooked Problem
Iron deficiency affects a large proportion of heart failure patients, even those who aren’t anemic. In heart failure, chronic inflammation traps iron inside storage cells, making it unavailable for the body to use. Medications commonly prescribed in heart failure, including blood thinners and antiplatelet drugs, also increase the risk of subtle blood loss.
Iron deficiency in heart failure is defined differently than in otherwise healthy people. Because inflammation artificially raises ferritin levels, the threshold is set higher: ferritin below 100, or ferritin between 100 and 300 with a transferrin saturation below 20%, both qualify. Intravenous iron is preferred over oral supplements because absorption from the gut is impaired in heart failure. Treating iron deficiency improves exercise capacity and quality of life regardless of whether you’re anemic, so it’s worth asking your care team to check your iron levels if they haven’t already.
Tracking Your Response to Treatment
A blood test measuring a protein called NT-proBNP helps gauge how hard your heart is working. In people without heart failure, levels are typically below 125 pg/mL. Higher levels correlate with greater strain on the heart. If your NT-proBNP is between 400 and 2,000 pg/mL, guidelines recommend specialist evaluation within six weeks. Above 2,000 pg/mL warrants evaluation within two weeks.
NT-proBNP is also useful for tracking treatment response over time. A 30% or greater drop from a previous measurement suggests treatment is working and may prompt your care team to continue increasing medication doses. A 10% or greater rise, on the other hand, may signal worsening function and trigger an increase in diuretics or a pause in other medication changes. These numbers help guide decisions between appointments, making regular blood work a valuable part of long-term management.
Advanced Options for Severe Heart Failure
For people whose symptoms remain severe despite full medication and device therapy, advanced interventions become part of the conversation. A left ventricular assist device (LVAD) is a mechanical pump surgically implanted to help the weakened left ventricle move blood forward. It can serve as a bridge while waiting for a heart transplant or as a long-term solution for people who aren’t transplant candidates.
LVAD candidacy is generally considered when someone has persistent, severe symptoms (classified as NYHA class III-B to IV) despite being on optimal medical and device therapy. Certain warning signs point toward the need for evaluation: two or more heart failure hospitalizations in the past year, needing to reduce medications because of low blood pressure or dizziness, requiring high doses of diuretics (above 160 mg per day of furosemide), persistently low blood sodium, or NT-proBNP levels above 5,000 pg/mL. On echocardiogram, an ejection fraction at or below 25% with a very enlarged left ventricle further supports the decision.
Heart transplantation remains the most definitive treatment for end-stage heart failure but is limited by organ availability and strict eligibility criteria. For those who qualify, survival rates after transplant have improved considerably, with most recipients returning to a much more active life.